Previous 10 | Next 10 |
- AACR Investor Event time change to 6:30 p.m. ET - - 21st Annual Needham Virtual Healthcare Conference Presentation April 13 th at 1:30 p.m. ET - Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing inno...
- Novel approach to CD28 to enhance activation of T cells and anti-tumor activity - - Crystallography demonstrates critical interaction between davoceticept’s CD80 domain and PD-L1 - - Data further encourage ongoing davoceticept development, including NEON-1 mon...
- Alpine to hold Investor Event on Tuesday, April 12 th at 6:00pm ET - Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today annou...
Alpine Immune Sciences press release (NASDAQ:ALPN): Q4 GAAP EPS of -$0.52 misses by $0.22. Revenue of $4.53M (-19.7% Y/Y) misses by $9.44M. For further details see: Alpine Immune Sciences GAAP EPS of -$0.52 misses by $0.22, revenue of $4.53M misses by $9.44M
- Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-30...
- NEON-1 Data Selected for Minisymposium Oral Presentation - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the accep...
Gainers: Clover Health Investments (NASDAQ:CLOV) +18%. Monte Rosa Therapeutics (NASDAQ:GLUE) +12%. Sharecare (NASDAQ:SHCR) +10%. InflaRx (NASDAQ:IFRX) +9%. Sigilon Therapeutics (NASDAQ:SGTX) +9%. Losers: Atreca (NASDAQ:BCEL) -30%. Biophytis (NASDAQ:BPTS) -14%. Alpine Immun...
The FDA has placed a partial clinical hold on a phase 2 trial of Alpine Immune Sciences' (NASDAQ:ALPN) davoceticept for advanced malignancies following a patient death. The company said the participant had received a single dose each of davoceticept and Keytruda (pembrolizumab). The caus...
-NEON-1 Study of ALPN-202 as a Monotherapy is Unaffected- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor con...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...